Introduction
The Mexican federal government has announced a single health credential initiative, presented by President Claudia Sheinbaum. This ambitious plan aims to integrate the fragmented public health system, including IMSS, ISSSTE, IMSS-Bienestar, Pemex, and Sedena. The initiative begins with providing free biometric and digital identification for all Mexicans, aiming to allow seamless healthcare access across federal units without losing clinical records by December.
Promises and Concerns
While the idea sounds promising, several concerns surround this project. The primary worry is citizens’ distrust in handling sensitive data, exacerbated by the politicization of information by the Morena government.
- Data Collection and Security: The mass collection of biometric data (fingerprints, facial recognition, possibly palm prints) and personal information like CURP, INE, and medical history poses a vulnerable scenario. Experts emphasize that premium technologies use mathematical cryptography to ensure security without storing live images. However, given Mexico’s history of prioritizing political agendas over transparency, these assurances seem hollow. There have been allegations regarding telecommunications and data laws that could potentially enable government surveillance. Although the president denies these claims, stating that communications remain protected, past incidents fuel skepticism. During election campaigns, there have been reports of misuse of databases like the INE’s electoral registry containing sensitive data from 90 million citizens, potentially exposed to manipulation.
- Previous Unfulfilled Health Initiatives: The persistent austerity makes it challenging to envision investments in top-tier providers, increasing the risk of leaks or misuse and further eroding trust in the already deteriorated public health system managing critical information like cancer diagnoses or chronic treatment plans.
Expert Opinions and Solutions
Fernando Casas from Identy.IO explains that current technology can streamline processes without massive investments of the past. However, for developing countries like Mexico with multiple dispersed databases (CURP, INE, SAT, Afores, etc.), unifying them is crucial. This requires cleaning, segmenting, and linking information to avoid duplicates, an essential step towards a “sovereign identity” enabling efficient digital services like online appointments or electronic medical prescriptions with proof of life.
Casas emphasizes that the barrier isn’t technological—biometric technology can be deployed quickly using basic mobile phones—but regulatory and political. This involves internal agreements, legal frameworks, coordination among hundreds of players, and proper medication logistics.
Challenges in Unifying Health Systems
Uniting IMSS (for private workers), ISSSTE (for bureaucrats), Pemex, and Sedena (for their affiliates), each with distinct coverage packages, seems impossible without first consolidating the 32 states under IMSS-Bienestar. Would the 4T only aim to unify the 24 adhering entities, neglecting the other 8?
Additional Health-Related News
Vaccination Centers in Bus Terminals and CDMX Metro?
Secretary of Health David Kershenobich mentioned on January 27 that vaccination centers could be opened in bus terminals and the CDMX metro to administer the measles vaccine. He acknowledged late arrival of vaccines but stressed sufficient stock and decreasing active sarampión cases, primarily in Jalisco, Michoacán, Sinaloa, and Guerrero.
Government to Invest $11,200 Million in Hospital Equipment
President Sheinbaum announced 24 hospitals to be built by 2026, with a planned investment of 45 billion pesos. Additionally, over $11,200 million will be invested in medical equipment for all health institutions. Subsecretary Eduardo Clark specified the acquisition of 816 high-tech devices to be distributed among the 32 federal entities, including IMSS, ISSSTE, IMSS-Bienestar, Pemex, and national health institutes and high-specialty hospitals under CCINSHAE.
Roche’s 2026 Strategy: Clinical Research, New Therapies, and Diagnostics
Roche reported that clinical research will be central to its 2026 strategy. In 2025, they conducted 81 clinical studies in 22 states involving 1,400 patients. Over 180 participated in a phase II study for obesity and excess weight, with phase III continuing in 2026. Roche plans to invest approximately $1,200 million this year in clinical research, launching 16 new studies in the first quarter with 1,200 patients. Their priority therapeutic areas include solid and hematological tumors, cardiometabolic diseases, nephrology, rheumatology, neurosciences, hemophilia, ophthalmology, and respiratory and infectious diseases. In 2026, they focus on diabetes, breast and lung cancer, multiple sclerosis, and spinal muscular atrophy, among others.
